| Summary: | Intact Transition Epitope Mapping—One-step Non-covalent force Exploitation (ITEM-ONE) analysis reveals an assembled epitope on the surface of Pertuzumab, which is recognized by the anti-Pertuzumab affimer 00557_709097. It encompasses amino acid residues NSGGSIYNQRFKGR, which are part of CDR2, as well as residues FTLSVDR, which are located on the variable region of Pertuzumab’s heavy chain and together form a surface area of 1381.46 Å<sup>2</sup>. Despite not being part of Pertuzumab’s CDR2, the partial sequence FTLSVDR marks a unique proteotypic Pertuzumab peptide. Binding between intact Pertuzumab and the anti-Pertuzumab affimer was further investigated using the Intact Transition Epitope Mapping—Thermodynamic Weak-force Order (ITEM-TWO) approach. Quantitative analysis of the complex dissociation reaction in the gas phase afforded a quasi-equilibrium constant (<inline-formula><math xmlns="http://www.w3.org/1998/Math/MathML" display="inline"><semantics><mrow><msubsup><mi mathvariant="normal">K</mi><mrow><mrow><mi mathvariant="normal">D</mi><mo> </mo><mi mathvariant="normal">m</mi></mrow><mn>0</mn><mi mathvariant="normal">g</mi></mrow><mo>#</mo></msubsup></mrow></semantics></math></inline-formula>) of 3.07 × 10<sup>−12</sup>. The experimentally determined apparent enthalpy (<inline-formula><math xmlns="http://www.w3.org/1998/Math/MathML" display="inline"><semantics><mrow><msubsup><mrow><mrow><mi mathvariant="sans-serif">Δ</mi><mi mathvariant="normal">H</mi></mrow></mrow><mrow><mi mathvariant="normal">m</mi><mn>0</mn><mi mathvariant="normal">g</mi></mrow><mo>#</mo></msubsup></mrow></semantics></math></inline-formula>) and apparent free energy (<inline-formula><math xmlns="http://www.w3.org/1998/Math/MathML" display="inline"><semantics><mrow><msubsup><mrow><mrow><mi mathvariant="sans-serif">Δ</mi><mi mathvariant="normal">G</mi></mrow></mrow><mrow><mi mathvariant="normal">m</mi><mn>0</mn><mi mathvariant="normal">g</mi></mrow><mo>#</mo></msubsup></mrow></semantics></math></inline-formula>) of the complex dissociation reaction indicate that the opposite reaction—complex formation—is spontaneous at room temperature. Due to strong binding to Pertuzumab and because of recognizing Pertuzumab’s unique partial amino acid sequences, the anti-Pertuzumab affimer 00557_709097 is considered excellently suitable for implementation in Pertuzumab quantitation assays as well as for the accurate therapeutic drug monitoring of Pertuzumab in biological fluids.
|
|---|